SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Infectious Diseases (tuberculosis) Consultation — Higuchi Ichiyō
| Patient | Higuchi Ichiyō |
|---|
| Date of birth | 2002-05-02 |
|---|
| Identifiers | MRN HR-NI029-SYN; SSN (made up) 000-29-5108 |
|---|
| Document date | 2026-04-17 |
|---|
| Author | Hiroshi Abernathy-Okoye, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Suspected pulmonary tuberculosis in a 23-year-old writer with seven weeks of cough, evening fevers, night sweats and 10 percent weight loss, and right upper lobe opacities without a cavity. Please see her at the results visit in three days to confirm the diagnosis, choose the regimen and doses, and advise on monitoring and infection control. [S]
Urgency: Urgent, at the results visit in three days. She is not short of breath at rest (oxygen saturation 96 percent) and has no hemoptysis. She is on airborne precautions at home, and the public health center has been told of the suspected case today. [S]
Questions for the consultant:
- Do her results confirm pulmonary tuberculosis if the sputum smears are negative?
- Which regimen do you advise: the standard six-month regimen or the four-month rifapentine-moxifloxacin regimen, and at what doses for her weight?
- Can she be treated as an outpatient, and when can she stop the precautions at home?
- What monitoring do you advise for liver injury, given her low weight and albumin, and for vision on ethambutol?
- When can ethambutol be stopped, and how long should the continuation phase be?
- What should the public health center's contact investigation cover?
History of Present Illness
Ms. Higuchi, a 23-year-old writer, is seen at the request of Dr. Lindgren-Tanaka at her results visit three days after her first visit. She describes about seven weeks of cough with a little white sputum, evening fevers, night sweats and weight loss, and she has been too tired to write for more than an hour or two. She has no hemoptysis, no known tuberculosis contact, no travel outside Japan, and no condition or medicine that weakens the immune system. She does not smoke or drink and takes no medicines. She lives with two adults and has stayed home with a mask in shared rooms since her first visit. She is anxious about the people she lives with and about the cost of treatment. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Higuchi Ichiyō, whose given name was Natsu (also written Natsuko), was born in Tokyo on the 25th day of the 3rd month of Meiji 5 in the Japanese lunisolar calendar, which is 2 May 1872 in the Gregorian calendar, in official housing within the grounds of the Tokyo prefectural office in Uchisaiwai-chō (now in Chiyoda). [D]
- Japan replaced its lunisolar calendar with the Gregorian calendar at the end of Meiji 5: the 3rd day of the 12th month of Meiji 5 became 1 January 1873 (Meiji 6). Dates before then, including her birth, were recorded in the old calendar. [D]
- From 1886 she studied classical poetry (waka) at the Haginoya academy of Nakajima Utako. [D]
- Her father died of illness in the summer of 1889, when she was 17, leaving debts from a failed business; she became head of the household and took on the support of her mother and younger sister, who did washing and needlework, and the family lived in poverty. [D]
- In 1891 she became a pupil of the novelist Nakarai Tōsui and began to write fiction, choosing to earn her living by writing at a time when this was very hard for a woman; her story Umoregi (1892) brought her into the literary world. [D]
- From July 1893 to April 1894 she ran a small shop selling household goods and cheap sweets in Shitaya Ryūsenji-chō, beside the Yoshiwara pleasure quarter (now in Taitō); the shop closed after about ten months, and her life there became material for Takekurabe. [D]
- In May 1894 she moved to Hongō Maruyama-Fukuyama-chō (now Nishikata, Bunkyō). [D]
- At Maruyama-Fukuyama-chō she wrote the works that made her name, among them Ōtsugomori (1894), Nigorie (1895), Takekurabe (1895 to 1896) and Jūsan'ya; Nippon.com calls the period 'the miraculous 14 months', and the Nipponica encyclopedia calls the time up to January 1896 'the miraculous year'. [D]
- From the beginning of 1896 her health declined rapidly. [D]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 2026-04-17 to 2026-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 2026-04-17 to 2026-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed |
R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed |
A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed |
E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed |
Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
Physical Exam
Vital signs recorded on 2026-04-17; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Thin and tired; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room |
| Respiratory | Fine crackles over the right upper zone |
| Eyes | No icterus |
| Abdomen | Liver not enlarged |
Assessment
- Pulmonary tuberculosis, smear-negative, Xpert-confirmed (A15.0). A positive Xpert MTB/RIF Ultra result in a patient with this history and X-ray confirms pulmonary tuberculosis even with negative smears; treatment should start today and not wait for culture. No rifampin resistance was detected and she has no risk factors for drug resistance. Smear-negative disease without a cavity carries a lower bacterial load and a lower risk of transmission. [S]
- Regimen choice (A15.0). The four-month rifapentine-moxifloxacin regimen requires a body weight of at least 40 kg, and she weighs 38.4 kg, so she is not eligible; the standard six-month regimen is recommended. Doses: isoniazid 200 mg (about 5 mg/kg), rifampin 450 mg (about 12 mg/kg, within the WHO range of 8 to 12 mg/kg, using 150 mg capsules), pyrazinamide 1000 mg (about 26 mg/kg) and ethambutol 600 mg (about 16 mg/kg), with pyridoxine because of her poor nutrition. Doses are reviewed if her weight changes by more than about 5 kg. [S]
- Moderate malnutrition and liver risk (E44.0). Low weight and albumin raise the risk of drug-induced liver injury, so liver tests at two weeks and monthly in the intensive phase are advised, in addition to symptom checks at every observed dose. If tests stay normal and albumin recovers, testing in the continuation phase can be for symptoms only. [S]
Data reviewed: Dr. Lindgren-Tanaka's intake note and results. Chest X-ray: right upper lobe opacities and small nodules without a cavity. Three sputum specimens, one on waking: smears negative for acid-fast bacilli; Xpert MTB/RIF Ultra on the first specimen detected Mycobacterium tuberculosis at a low level with no rifampin resistance; cultures pending. HIV antigen and antibody test, hepatitis B surface antigen and core antibody, hepatitis C antibody and pregnancy test negative; hepatitis B surface antibody negative. Liver and kidney tests normal; albumin 3.3 g/dL; hemoglobin 11.4 g/dL; hemoglobin A1c 5.1%. Visual acuity 85 letters in each eye; color vision normal. Weight today 38.4 kg. [S]
Plan of Treatment
- Start isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg, ethambutol 600 mg and pyridoxine 50 mg daily today, by daily video-observed therapy with the public health center. [S]
- Outpatient treatment is appropriate for smear-negative disease without a cavity in a patient who can stay home; continue home precautions until she has had two weeks of treatment and is improving, then end them with the public health center's agreement. [S]
- Liver tests at two weeks and monthly in the intensive phase; visual acuity and color vision at two weeks and monthly while on ethambutol; stop the drugs and call the same day for hepatitis symptoms or any change in vision. [S]
- Stop ethambutol as soon as the isolate is shown to be susceptible to isoniazid and rifampin. [S]
- Sputum smear and culture at two weeks and at two months; without a cavity the continuation phase is four months of isoniazid and rifampin; consider seven months if the two-month culture is positive, because she is underweight. [S]
- Notify the public health center at once on diagnosis; its contact investigation should cover the household first, then other close contacts with hours of shared indoor air during the infectious period, such as visiting editors. [S]
- Counsel her that rifampin makes hormonal contraceptives unreliable and interacts with many medicines; avoid fluoroquinolones for other infections during treatment. [S]
- Chest X-ray at the end of treatment as a new baseline. [S]
- Discussed with Dr. Lindgren-Tanaka the same morning; she continues the prescribing and monitoring with the public health center. Ms. Higuchi was told that tuberculosis is curable with six months of treatment, that she will soon stop being infectious, and that most of the costs are covered by public funding; she asked how soon she could write again and was encouraged to begin with short sessions once the fevers settle. [S]
- Follow-up: Available by phone to Dr. Lindgren-Tanaka for the susceptibility results and any adverse effect; review again if a drug has to be stopped. [S]